CH647534A5 - Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate. - Google Patents
Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate. Download PDFInfo
- Publication number
- CH647534A5 CH647534A5 CH10311/79A CH1031179A CH647534A5 CH 647534 A5 CH647534 A5 CH 647534A5 CH 10311/79 A CH10311/79 A CH 10311/79A CH 1031179 A CH1031179 A CH 1031179A CH 647534 A5 CH647534 A5 CH 647534A5
- Authority
- CH
- Switzerland
- Prior art keywords
- chamomile
- cyclodextrin
- complex
- complexes
- drug
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 12
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 240000003538 Chamaemelum nobile Species 0.000 claims description 53
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 52
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 45
- 229920000858 Cyclodextrin Polymers 0.000 claims description 32
- 239000003814 drug Substances 0.000 claims description 20
- 229940079593 drug Drugs 0.000 claims description 20
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 19
- 238000002360 preparation method Methods 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 14
- 239000003205 fragrance Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 9
- 235000019568 aromas Nutrition 0.000 claims description 7
- 229920002472 Starch Polymers 0.000 claims description 6
- 241000783476 Achillea collina Species 0.000 claims description 5
- 239000011541 reaction mixture Substances 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 230000009918 complex formation Effects 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 239000000314 lubricant Substances 0.000 claims description 3
- 238000000855 fermentation Methods 0.000 claims description 2
- 230000004151 fermentation Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000008406 cosmetic ingredient Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000000047 product Substances 0.000 description 25
- 239000004480 active ingredient Substances 0.000 description 17
- 241001465754 Metazoa Species 0.000 description 15
- 239000010628 chamomile oil Substances 0.000 description 15
- 235000019480 chamomile oil Nutrition 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 13
- 239000003921 oil Substances 0.000 description 13
- 235000019198 oils Nutrition 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 239000001116 FEMA 4028 Substances 0.000 description 11
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 11
- 229960004853 betadex Drugs 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 235000019786 weight gain Nutrition 0.000 description 10
- 230000004584 weight gain Effects 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 9
- 239000000843 powder Substances 0.000 description 9
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 241001122767 Theaceae Species 0.000 description 6
- VETGQECQXHDROF-UHFFFAOYSA-N azulen-1-ol Chemical compound C1=CC=CC=C2C(O)=CC=C21 VETGQECQXHDROF-UHFFFAOYSA-N 0.000 description 6
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 6
- 238000000354 decomposition reaction Methods 0.000 description 6
- 208000004232 Enteritis Diseases 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 235000020346 chamomile tea Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000008030 elimination Effects 0.000 description 5
- 238000003379 elimination reaction Methods 0.000 description 5
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 239000013543 active substance Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- CUFNKYGDVFVPHO-UHFFFAOYSA-N azulene Chemical compound C1=CC=CC2=CC=CC2=C1 CUFNKYGDVFVPHO-UHFFFAOYSA-N 0.000 description 4
- 229960001340 histamine Drugs 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 229960005070 ascorbic acid Drugs 0.000 description 3
- 235000010323 ascorbic acid Nutrition 0.000 description 3
- 239000011668 ascorbic acid Substances 0.000 description 3
- 239000003651 drinking water Substances 0.000 description 3
- 235000020188 drinking water Nutrition 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 3
- 239000001095 magnesium carbonate Substances 0.000 description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 3
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 3
- 230000036284 oxygen consumption Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 244000038022 Chenopodium capitatum Species 0.000 description 2
- 235000004391 Chenopodium capitatum Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010010741 Conjunctivitis Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 229940097362 cyclodextrins Drugs 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 235000021050 feed intake Nutrition 0.000 description 2
- 150000002213 flavones Chemical class 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 2
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 210000001539 phagocyte Anatomy 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000010334 sieve classification Methods 0.000 description 2
- 230000035943 smell Effects 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- YXCPDVDLUQEPKX-UHFFFAOYSA-N 2h-azulen-1-one Chemical compound C1=CC=CC=C2C(=O)CC=C21 YXCPDVDLUQEPKX-UHFFFAOYSA-N 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 229940119217 chamomile extract Drugs 0.000 description 1
- 235000020221 chamomile extract Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000021051 daily weight gain Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 210000000613 ear canal Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- -1 flavone compound Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- LIIALPBMIOVAHH-UHFFFAOYSA-N herniarin Chemical compound C1=CC(=O)OC2=CC(OC)=CC=C21 LIIALPBMIOVAHH-UHFFFAOYSA-N 0.000 description 1
- JHGVLAHJJNKSAW-UHFFFAOYSA-N herniarin Natural products C1CC(=O)OC2=CC(OC)=CC=C21 JHGVLAHJJNKSAW-UHFFFAOYSA-N 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 235000020344 instant tea Nutrition 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004086 maxillary sinus Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000011022 opal Substances 0.000 description 1
- 239000004482 other powder Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960000321 oxolinic acid Drugs 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N p-menthan-3-ol Chemical compound CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012450 pharmaceutical intermediate Substances 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000012797 qualification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/738—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/12—Face or body powders for grooming, adorning or absorbing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q9/00—Preparations for removing hair or for aiding hair removal
- A61Q9/02—Shaving preparations
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Birds (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Nanotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU78CI1867A HU176217B (en) | 1978-11-20 | 1978-11-20 | Process for preparing a cyclodextrin-chamomille inclusion complex and compositions containing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CH647534A5 true CH647534A5 (de) | 1985-01-31 |
Family
ID=10994713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CH10311/79A CH647534A5 (de) | 1978-11-20 | 1979-11-19 | Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate. |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JPS5573617A (it) |
| AT (1) | AT363176B (it) |
| BE (1) | BE880155A (it) |
| CH (1) | CH647534A5 (it) |
| CS (1) | CS223972B2 (it) |
| DD (1) | DD146893A1 (it) |
| DE (1) | DE2944350A1 (it) |
| DK (1) | DK491679A (it) |
| ES (1) | ES486109A1 (it) |
| FI (1) | FI68174C (it) |
| FR (1) | FR2441389A1 (it) |
| GB (1) | GB2037306B (it) |
| HU (1) | HU176217B (it) |
| IT (1) | IT1119944B (it) |
| NL (1) | NL7908354A (it) |
| NO (1) | NO155625C (it) |
| PL (1) | PL126984B1 (it) |
| SE (1) | SE7909505L (it) |
| SU (1) | SU1514240A3 (it) |
| YU (1) | YU280379A (it) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU184066B (en) | 1979-12-28 | 1984-06-28 | Chinoin Gyogyszer Es Vegyeszet | Plant growth regulating substance and process for preparing such compound |
| JPS5724306A (en) * | 1980-07-16 | 1982-02-08 | Wakunaga Yakuhin Kk | Preparation of solid chinese herbal pharmaceutical |
| HU180183B (en) * | 1980-12-19 | 1983-02-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing stable suppository compositions containing volatile and/or labile active substances |
| JPS5830032B2 (ja) * | 1981-02-18 | 1983-06-27 | 呉羽化学工業株式会社 | ビフイダス菌の増殖剤 |
| JPS5813541A (ja) | 1981-07-16 | 1983-01-26 | Kureha Chem Ind Co Ltd | エイコサペンタエン酸又はドコサヘキサエン酸のシクロデキストリン包接化合物 |
| JPS5920230A (ja) * | 1982-07-19 | 1984-02-01 | チバ−ガイギ−・アクチエンゲゼルシヤフト | ピルプロフエン含有薬剤 |
| GB2179551A (en) * | 1984-09-01 | 1987-03-11 | Jeanette Hill | Hair treatment preparations |
| FR2578422B1 (fr) * | 1985-03-05 | 1987-06-26 | Cariel Leon | Composition de traitement a usage topique externe a base de luteoline et procede de preparation |
| HU196306B (en) * | 1985-04-01 | 1988-11-28 | Chinoin Gyogyszer Es Vegyeszet | New dusting powders comprising bioactive material and process for preparing the same |
| EP0211392B1 (en) * | 1985-08-06 | 1991-03-27 | Kao Corporation | Liquid shampoo composition |
| WO1990013305A1 (en) * | 1989-04-28 | 1990-11-15 | Kooperativ 'vivaton' | Pharmaceutical preparation for treatment of mastitis in animals and humans |
| DE4338508A1 (de) * | 1993-11-11 | 1995-05-18 | Asta Medica Ag | Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlußverbindungen mit Cyclodextrinen oder Cyclodextrinderivaten und in Form von Granulaten, Kau- oder Brausetabletten |
| CA2211222A1 (en) * | 1996-09-04 | 1998-03-04 | Warner-Lambert Company | Shaving aid with complexing agent |
| DE19746284A1 (de) * | 1997-10-20 | 1999-04-22 | Robugen Gmbh | Kosmetische und pharmazeutische Mittel auf Basis eines Kamillenextraktes |
| ES2171147B1 (es) * | 2001-02-06 | 2003-12-16 | Esteve Labor Dr | Preparacion para usos veterinarios. |
| AU2003278559A1 (en) * | 2002-10-17 | 2004-05-04 | David Nakar | Herbal medicine containing cyclodextrins for the treatment of ear disorders |
| FR2898817B1 (fr) * | 2006-03-23 | 2008-08-08 | Univ Rouen | Association de substance oleagineuse avec un melange d'au moins deux cyclodextrines |
| JP2009091309A (ja) * | 2007-10-10 | 2009-04-30 | Japan Organo Co Ltd | バコパモニエラエキスを含有する組成物およびその製造方法ならびに飲食品 |
| CN114533896B (zh) * | 2020-11-26 | 2024-05-31 | 江西济民可信集团有限公司 | 一种包合物及其制备方法、应用、含其的金芩花颗粒 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5443570B2 (it) * | 1972-10-27 | 1979-12-20 | ||
| JPS5423966B2 (it) * | 1972-11-11 | 1979-08-17 | ||
| JPS5017529B2 (it) * | 1972-11-20 | 1975-06-21 | ||
| JPS53126089A (en) * | 1977-04-11 | 1978-11-02 | Akiyama Jiyouzai Kk | Cyclodextrin clathrate compound including safflower oil |
| HU174699B (hu) * | 1977-07-01 | 1980-03-28 | Chinoin Gyogyszer Es Vegyeszet | Sposob poluchenija natural'nykh i sinteticheskikh ciklodektrinnykh okkluzionnykh kompleksov prjaznostej, aromatov i vkusnykh vehhestv |
-
1978
- 1978-11-20 HU HU78CI1867A patent/HU176217B/hu unknown
-
1979
- 1979-11-02 DE DE19792944350 patent/DE2944350A1/de not_active Ceased
- 1979-11-08 FI FI793504A patent/FI68174C/fi not_active IP Right Cessation
- 1979-11-08 GB GB7938763A patent/GB2037306B/en not_active Expired
- 1979-11-12 CS CS797712A patent/CS223972B2/cs unknown
- 1979-11-15 NL NL7908354A patent/NL7908354A/nl not_active Application Discontinuation
- 1979-11-15 YU YU02803/79A patent/YU280379A/xx unknown
- 1979-11-16 SE SE7909505A patent/SE7909505L/xx unknown
- 1979-11-16 FR FR7928299A patent/FR2441389A1/fr active Granted
- 1979-11-16 IT IT69222/79A patent/IT1119944B/it active
- 1979-11-19 NO NO793731A patent/NO155625C/no unknown
- 1979-11-19 CH CH10311/79A patent/CH647534A5/de not_active IP Right Cessation
- 1979-11-19 ES ES486109A patent/ES486109A1/es not_active Expired
- 1979-11-19 JP JP14992679A patent/JPS5573617A/ja active Pending
- 1979-11-19 DD DD79216972A patent/DD146893A1/de not_active IP Right Cessation
- 1979-11-19 SU SU792849102A patent/SU1514240A3/ru active
- 1979-11-19 DK DK491679A patent/DK491679A/da not_active Application Discontinuation
- 1979-11-20 AT AT0738579A patent/AT363176B/de not_active IP Right Cessation
- 1979-11-20 PL PL1979219739A patent/PL126984B1/pl unknown
- 1979-11-20 BE BE0/198200A patent/BE880155A/fr not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| FR2441389A1 (fr) | 1980-06-13 |
| FI793504A (fi) | 1980-05-21 |
| NL7908354A (nl) | 1980-05-22 |
| GB2037306A (en) | 1980-07-09 |
| SE7909505L (sv) | 1980-05-21 |
| SU1514240A3 (ru) | 1989-10-07 |
| BE880155A (fr) | 1980-03-17 |
| CS223972B2 (en) | 1983-11-25 |
| NO155625C (no) | 1987-04-29 |
| PL219739A1 (it) | 1980-12-01 |
| PL126984B1 (en) | 1983-09-30 |
| NO793731L (no) | 1980-05-21 |
| DD146893A1 (de) | 1981-03-11 |
| GB2037306B (en) | 1983-06-15 |
| DK491679A (da) | 1980-05-21 |
| NO155625B (no) | 1987-01-19 |
| HU176217B (en) | 1981-01-28 |
| ES486109A1 (es) | 1980-09-01 |
| FI68174C (fi) | 1985-08-12 |
| FI68174B (fi) | 1985-04-30 |
| AT363176B (de) | 1981-07-10 |
| IT7969222A0 (it) | 1979-11-16 |
| YU280379A (en) | 1984-12-31 |
| ATA738579A (de) | 1980-12-15 |
| JPS5573617A (en) | 1980-06-03 |
| DE2944350A1 (de) | 1980-05-29 |
| FR2441389B1 (it) | 1984-02-10 |
| IT1119944B (it) | 1986-03-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH647534A5 (de) | Cyclodextrin-kamillen-inklusionskomplexe, verfahren zur herstellung der komplexe und die komplexe enthaltenden praeparate. | |
| DE69617945T2 (de) | Pharmazeutische zubereitungen, auf der basis von pflanzlichen etherischen ölen für die verwendung im menschlichen oder veterinären medizinischem bereich | |
| DE69320919T2 (de) | Organische pestizide | |
| DE3500179C2 (it) | ||
| US5561116A (en) | Solid product containing propolis components, and preparation and uses thereof | |
| DE2710327B2 (de) | Verwendung von Benzaldehyd | |
| DE3511609C2 (it) | ||
| DE4212132A1 (de) | Propolisbestandteile enthaltendes feststoffprodukt, seine herstellung und verwendung | |
| DE3638124C2 (de) | Neue pharmazeutische Verwendung von Ebselen | |
| DE60308045T2 (de) | Pflanzenextrakte aus argyrolobium roseum zur behandlung von diabetes | |
| DE2850509C3 (de) | O-Methoxyzimtaldehyd bei der Bekämpfung von Dermatophyten | |
| EP1429795B1 (de) | Verfahren zur herstellung von extrakten aus pelargonium sidoides und/oder pelargonium reniforme | |
| DE2349538C2 (de) | Arzneimittel zur Behandlung von Lebererkrankungen | |
| EP1021198A1 (de) | Flavonolignan-zubereitungen, insbesondere silymarin-zubereitungen | |
| DE4102054A1 (de) | Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe | |
| EP2793917B1 (de) | Extrakt aus rhus copallina zur verwendung als arzneimittel | |
| DE2243777A1 (de) | Dihydrochinolinderivate, ihre verwendung und verfahren zur herstellung derselben | |
| CH644018A5 (de) | Pharmazeutisches mittel zur prostaglandinregulierung. | |
| DE60023585T2 (de) | Zubereitung eines Arzneimittels enthaltend Catechich- oder Flavonylisch-ähnliche Polyphenolverbindungen aus Pflanzen, insbesondere für die Behandlung von Gingivitis | |
| DE2047049C3 (de) | Calciumsalz der 6-(N-Acetylamino)hexansSure, Verfahren zu seiner Herstellung und Arzneimittel mit einem Gehalt an diesem Salz | |
| DE2417993A1 (de) | Megluminkomplexe antimykotischer polyenantibiotika, der makrolide, verfahren zu ihrer herstellung und arzneimittel auf der basis dieser stoffe | |
| DE2005255C3 (de) | Verwendung von Ca-5-butylpicolinat und/oder Ca-5-pentylpicolinat zur Herstellung eines blutdrucksenkenden Arzneimittels | |
| DE2609533B2 (de) | Verfahren zur Extraktion von Wirkstoffen, insbesondere von Heterosidestern der Kaffeesäure, sowie diese Verbindungen enthaltende Arzneimittel | |
| DE10255481A1 (de) | Pharmazeutische Zubereitungen umfassend mittels Extraktion mit überkritischen Flüssigkeiten hergestellte Hopfenextrakte zur Verwendung als Sedativa | |
| DE10085492T5 (de) | Antimonocytenaktivität von extrakten von Betelpfefferblättern |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PL | Patent ceased | ||
| PL | Patent ceased |